A significant dilemma in the treatment of heart failure patients with sacubitril/valsartan or sodium-glucose co-transporter 2 inhibitors: Whether to add mineralocorticoid receptor antagonists
Dimitrios Patoulias,
Christodoulos Papadopoulos,
Konstantinos Stavropoulos,
Konstantinos Imprialos,
Aristi Boulmpou,
Michael Doumas
Affiliations
Dimitrios Patoulias
Second Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, General Hospital “Hippokration”, Greece; Corresponding author.
Christodoulos Papadopoulos
Third Department of Cardiology, Aristotle University of Thessaloniki, General Hospital “Hippokration”, Greece
Konstantinos Stavropoulos
Second Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, General Hospital “Hippokration”, Greece
Konstantinos Imprialos
Second Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, General Hospital “Hippokration”, Greece
Aristi Boulmpou
Third Department of Cardiology, Aristotle University of Thessaloniki, General Hospital “Hippokration”, Greece
Michael Doumas
Second Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, General Hospital “Hippokration”, Greece; Veterans Affairs Medical Center, George Washington University, Washington, District of Columbia, United States
